argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
argenx reported Q2 2026 product net sales of $1.5 billion, representing 60% year-over-year growth and 17% quarter-over-quarter growth, driven by strong demand for VYVGART. The company successfully launched the expanded label for VYVGART and VYVGART Hytrulo to include all gMG serotypes, while registrational study readouts for myositis and MMN remain on track for the second half of 2026.
Key figures
- Eps
- 7.32
- Revenue
- 1516000000
- Revenue Yoy
- 60%
- Total liquidity
- 5200000000
- Operating profit
- 494000000
- Cash and equivalents
- 3600000000
- Product net sales h1
- 2813000000
- Current financial assets
- 1600000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.